GeneDx Announces Evolution of Executive Leadership Team
11 Setembro 2023 - 9:00AM
GeneDx (Nasdaq: WGS) a leader in delivering improved health
outcomes through genomic and clinical insights, today announced the
expansion and evolution of its executive leadership team with the
appointment of Melanie Duquette as Chief Growth Officer and
Jennifer (Jen) Brendel as Chief of Corporate Affairs. Both
executives will report to Katherine Stueland, CEO and President,
and will collaborate in continuing to strengthen GeneDx’s market
leading position in genomic interpretation and health insights.
Bringing nearly 20 years of genomic industry experience, in her
role as Chief Growth Officer, Melanie will be responsible for the
company’s overall growth strategy and will lead the sales, market
access, clinician marketing and client services functions. Melanie
joins GeneDx from Invitae where she spent the past decade driving
commercial growth strategies to expand utilization of genetic
testing. Most recently, she served as the Head of US Sales for
Invitae, leading a sales and business development organization of
more than 200 people and executing a commercial strategy that
shifted the team towards profitable growth with a focus on
increased ASPs. Prior to that, she led the company’s entry and
rapid expansion into more than 100 international markets.
“Over the past two years, our goal has been to drive utilization
of our industry-leading whole exome and genome sequencing testing
to help deliver more comprehensive and definitive diagnoses to as
many patients as possible. We continue to deliver on that goal, and
we are thrilled to add Melanie’s leadership and talents as we enter
a new chapter of commercial success,” said Stueland. “Critically
important to our mission is amplifying the GeneDx brand and
commitment to clinical leadership across all constituents – current
and future customers, patient advocates, policymakers, investors
and media – and Jen can now help us ramp up a necessary part of our
long-term growth strategy. The combined expertise and passion of
these two leaders will ensure GeneDx realizes the next chapter of
growth and brand transformation and accelerates the adoption and
utilization of exome and genome testing.”
In her previous position as Chief Commercial Officer for GeneDx,
Jen Brendel set the foundation of the commercial footprint and
strategy for the Company, which has contributed to the accelerated
utilization of exome and genome testing and 40% revenue growth from
2021 to 2022 with continued growth of product mix to 22% in Q2. In
her new role, she will be responsible for amplifying the GeneDx
leadership position and voice in critical healthcare discussions
and will lead the brand, communications, government affairs and
investor relations functions. To these efforts, she will bring her
more than two decades of diverse commercial experience, spanning
all product lifecycle stages and commercial functions, including
sales, marketing, business development and communications. Prior to
joining GeneDx, Jen served both domestically and abroad in
leadership positions as part of US, regional and global teams for
Pfizer, Bayer and Invitae, among other organizations.
About GeneDx GeneDx (Nasdaq: WGS) delivers
personalized and actionable health insights to inform diagnosis,
direct treatment and improve drug discovery. The company is
uniquely positioned to accelerate the use of genomic and
large-scale clinical information to enable precision medicine as
the standard of care. GeneDx is at the forefront of transforming
healthcare through its industry-leading exome and genome testing
and interpretation, fueled by one of the world’s largest, rare
disease data sets. For more information, please
visit www.genedx.com and connect with us on LinkedIn,
Facebook, Twitter and Instagram.
GeneDx Investor Relations Contact: Tricia Truehart
Investors@GeneDx.com
GeneDx Media Contact: Teca Lewellyn Press@GeneDx.com
GeneDx (NASDAQ:WGS)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
GeneDx (NASDAQ:WGS)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024